CTRI/2021/07/035244已完成4 期
Multicentre phase IV Single arm clinical trial to evaluate the safety and Efficacy of Gla-300 in insulin-naïve patients with Type 2 Diabetes uncontrolled on oral anti-hyperglycemic drugs
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 222
- 试验地点
- 14
- 主要终点
- Percentage of participants with Treatment Emergent Adverse Events (TEAEs) including serious adverse events (SAEs) and hypoglycemic episodes
研究概览
简要总结
This study is being done to meet the regulatory requirements ofconducting a Phase 4 clinical trial for Gla-300 with more than 200 Indianparticipants. This India-specific study will evaluate the safety and efficacyof insulin glargine 300 U/mL in insulin naïve participants with T2D.
At present, the most widely used basal insulin is insulin glargine 100U/ml (Gla-100), which has a well-established mode of action, and efficacy and safetyprofile. However, to improve current treatment options, a basal insulinconferring an even lower risk of hypoglycemia would be desirable.
New insulin glargine 300 U/ml (Gla-300) has been developed to optimizeglycemic control, while minimizing the risk of hypoglycemia. After subcutaneous(s.c.) injection, the pharmacokinetic and pharmacodynamic action profiles ofGla-300 were more constant and prolonged compared with those of Gla-100, as a result of a more gradualand extended release of glargine from the s.c. depot. This translates intocontinued blood glucose control beyond 24 h.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 55.00 Year(s)（—）
- 性别
- All
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply: Age I
- •Participant must be 18 years of age inclusive, at the time of signing the informed consent Type of participant and disease characteristics I
- •Participants with type 2 diabetes mellitus.
- •Participants who are insulin naïve on at least one oral antihyperglycemic drug (metformin, sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT-2 inhibitor, glinide, α-glucosidase inhibitor) with or without glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for a minimum period of 6 months prior to screening.
- •The background non-insulin antidiabetic drug should be administered at stable dose for at least 8 weeks prior to screening Sex I
- •Male or female Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP).
- •OR A WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 1 week after the last dose of study intervention (i.e., until Week 27).
- •Informed Consent I
- •Capable of giving signed informed consent as described in Appendix 1 of the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Other criteria I
- •HbA1c between 7.5% (58 mmol/mol) and 10% (86 mmol/mol) inclusive, during screening.
- •Median of the last 3 consecutive fasting self-monitored blood glucose (SMBG)values prior to baseline, or at least 2 fasting SMBG values in the week prior to baseline >130 mg/dL.
排除标准
- •Participants are excluded from the study if any of the following criteria apply: Medical conditions E
- •Any clinically significant abnormality identified either in medical history or during screening evaluation (e.g., physical examination, laboratory tests, electrocardiogram, vital signs) or any AEs during screening period, which in judgment of the Investigator would preclude safe completion of the study or constrains efficacy assessment.
- •History of severe hypoglycemia requiring emergency room admission or hospitalization within 3 months prior to screening visit.
- •Proliferative retinopathy or maculopathy requiring treatment according to the Investigator Prior/concomitant therapy E
- •Treatment with any insulin including basal insulin, mixed insulin (premixes), rapid insulin, and fast-acting insulin analogues in the last 6 months before screening visit (use ≤10 days in relation to hospitalization or an acute illness is accepted).
- •Use of non-insulin anti-hyperglycemic drugs other than those listed in inclusion criteria.
- •Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 2 weeks or more within 8 weeks prior to screening visit.
- •Likelihood to require treatment prohibited by the protocol during the study Prior/concurrent clinical study experience E
- •Exposure to any investigational drugs in the last 4 weeks or 5 half-lives, whichever is longer, prior to screening visit or concomitant enrollment in any other clinical study involving an investigational study treatment.
- •Other exclusions E
- •Any specific situation during study implementation/course that may raise ethics considerations.
- •History of hypoglycemia unawareness.
- •Hypersensitive to insulin glargine or any of the excipients E
- •History of drug or alcohol abuse within 6 months prior to screening visit.
- •Additional criteria at the end of the screening period E
- •Participants unwilling or unable to comply with study procedures as outlined in the protocol E
- •Participants who withdraw consent during the screening (starting from signed ICF).
结局指标
主要结局
Percentage of participants with Treatment Emergent Adverse Events (TEAEs) including serious adverse events (SAEs) and hypoglycemic episodes
时间窗: week 24
End point:
时间窗: week 24
Objective:
时间窗: week 24
To evaluate the safety of Gla-300 in insulin naïve T2D participants uncontrolled on oral antihyperglycemic Drugs
时间窗: week 24
次要结局
- Objective:(To assess the efficacy of Gla-300 on glycemic control in insulin naïve T2D participants uncontrolled on oral anti-hyperglycemic drugs)
- End point:(Percentage of participants with at least 1 confirmed (Level 1) hypoglycemia event from baseline to Week 24.)
研究者
研究点 (14)
Loading locations...
相似试验
进行中（未招募）
4 期
A clinical trial to study effects of Teriparatide in the Treatment of Postmenopausal Osteoporosis.CTRI/2023/05/052618Enzene Biosciences Limited200
已完成
4 期
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the KneeOsteoarthritis of KneeNCT02682524Daewon Pharmaceutical Co., Ltd.191
尚未招募
4 期
Safety and efficacy of Brinzolamide and Timolol eye drops to decrease intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension for whom single drug therapy provides insufficient for intraocular pressure reductionCTRI/2023/05/052720Sun Pharma Laboratories Limited (SPLL)155
已完成
4 期
A clinical study to see the effect and safety of Phenocaine Plus Injection in Cataract Surgery.CTRI/2021/04/032545Entod Pharmaceuticals Ltd219
已完成
4 期
A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a TaxaneHER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast CancerNCT02658734Hoffmann-La Roche70